A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Biropepimut-S (Primary) ; Cyclophosphamide (Primary) ; Poly ICLC (Primary) ; Sargramostim (Primary)
  • Indications Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Gliknik
  • Most Recent Events

    • 28 Aug 2017 According to a Gliknik Inc. media release, clinicians have enrolled and dosed the first of 80 patients in this trial.
    • 05 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 10 Mar 2017 Planned initiation date changed from 1 Nov 2016 to 31 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top